ArticleMetabolic brain disease2025
Ginkgo biloba extract mediates HT22 cell proliferation and migration after oxygen-glucose deprivation/reoxygenation via regulating RhoA-ROCK2 signalling pathway.
Article in Metabolic brain disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vascular dementia (VD) is a neurocognitive disorder resulting from cerebral vascular disorders, leading to the demise of neurons and cognitive deficits, posing significant health concerns globally. Derived from Ginkgo biloba leaves, EGb761 is a potent bioactive compound widely recognized for its benefits in treating cerebrovascular diseases. Previous studies have demonstrated that the administration of EGb761 to VD rats enhances the proliferation, differentiation, and migration of neurons, effectively alleviating cognitive dysfunction. However, the specific mechanisms by which EGb761 exerts its remedial influence on VD persist in ambiguity. This investigation utilized an integrated approach incorporating network pharmacology with experimental procedures on HT-22 mouse hippocampal neuronal cells amidst oxygen-glucose deprivation and reoxygenation (OGD/R) to delve into certain repercussions of EGb761 on cell proliferation and migration. Results revealed that ras homolog family member A (RHOA) and B-cell lymphoma 2 (BCL-2) are potential targets of Ginkgo biloba leaves. Target genes are mainly enriched in pathways including those involved in growth hormone synthesis, secretion and action and the neurotrophin signalling pathway. Cellular experiments further demonstrated that the application of EGb761 notably enhanced the viability, proliferation, and migration of HT22 cells subjected to OGD/R through RhoA-ROCK2 pathway. In conclusion, our findings indicated that EGb761 significantly enhances neuronal proliferation and migration following OGD/R injury by targeting the RhoA-ROCK2 signalling pathway, thus offering valuable insights into its potential as a treatment for VD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.